Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Feb;32(1):71-5.
doi: 10.1007/s10792-011-9513-1. Epub 2012 Jan 22.

Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

Affiliations
Case Reports

Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

Vincenzo Russo et al. Int Ophthalmol. 2012 Feb.

Abstract

The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.

PubMed Disclaimer

References

    1. Retina. 2006 Mar;26(3):275-8 - PubMed
    1. Indian J Ophthalmol. 2005 Dec;53(4):274-5 - PubMed
    1. Ann Oncol. 1997 Oct;8(10):1015-22 - PubMed
    1. Ophthalmology. 1999 Mar;106(3):623-9 - PubMed
    1. Retina. 2002 Apr;22(2):228-32 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources